Veeva Systems Company Profile (NYSE:VEEV)

Veeva Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "VEEV."

Veeva Systems Inc. (NYSE:VEEV) announced its quarterly earnings results on Thursday, August, 24th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. The business had revenue of $166.59 million for the quarter, compared to analyst estimates of $164.26 million. Veeva Systems had a net margin of 18.98% and a return on equity of 12.77%. The company's revenue was up 26.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.15 EPS. View Veeva Systems' Earnings History.

Veeva Systems is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for Veeva Systems.

Veeva Systems updated its FY18 earnings guidance on Thursday, August, 24th. The company provided earnings per share (EPS) guidance of $0.86-0.87 for the period, compared to the Thomson Reuters consensus estimate of $0.83. The company issued revenue guidance of $672-674 million, compared to the consensus revenue estimate of $669.86 million.Veeva Systems also updated its Q3 guidance to $0.21-0.22 EPS.

12 analysts have issued 1-year price targets for Veeva Systems' stock. Their forecasts range from $43.00 to $70.00. On average, they expect Veeva Systems' stock price to reach $63.92 in the next year. View Analyst Ratings for Veeva Systems.

Here are some recent quotes from research analysts about Veeva Systems stock:

• 1. KeyCorp analysts commented, "We are raising revenue estimates by $5M in F2018 and nearly $10M in F2019 based on the assumption that (1) Vault growth remains at or above 40%, and (2) Commercial Cloud plus services can sustain growth at or above 10% y/y." (8/25/2017)
• 2. According to Zacks Investment Research, "Veeva Systems outperformed the broader industry in the last three months on the back of its splendid earnings surprise history. Notably, the company has delivered positive earnings surprise in all the past four quarters. Further, the company remains on track with its commercial cloud platform, which registered multiple contracts around the world. Veeva has also many core CRM projects on track with large pharma companies around the globe. The company has strengthened the recurring part of its revenue mix by marking significant growth in subscription revenues in the reported quarter. Moreover, the new launches at the Veeva Vault and the Veeva Coomercial Cloud platforms are encouraging. Estimates have been stable ahead of the company's second quarter earnings release. However, intensifying competition, high operating expenses and a saturating lifesciences market are key concerns." (7/27/2017)
• 3. Bank of America Corporation analysts commented, "greater confidence" that the company is in the early stages of a multi-billion-dollar revenue opportunity with Vault. In fact, the analyst sees Veeva's Vault opportunity in both the large pharmaceutical installed base (which presents an additional $400 to $500 million revenue opportunity) along with life sciences start-ups, which was previously un-addressed.Sills also noted that commercial could also sustain a "health" mid-teens growth rate due to: 1) cross selling of PromoMats, 2) cross-selling CRM add-ons, 3) expansion in the already existing installed base and 4) new customer wins intentionally, especially in Japan and Europe. Finally, the analyst explained that his new $70 price target represents a 42x EV/FCF multiple on his 2018 estimates which is "reasonable" relative to the analyst's estimated three-year FCF compounded annual growth rate of 30 percent, which is likely to be proven conservative. At time of publication, shares of Veeva were up 6.33 percent at $65.65." (5/26/2017)
• 4. Stifel Nicolaus analysts commented, "On February 28th, after the market close, Veeva delivered F4Q17 financial results that came in ahead of consensus across all key metrics. Highlights in the quarter included the two largest Vault deals in the company's history and a top-20 pharma selecting Veeva for a standardization of Veeva CRM across its domestic Japanese operations. Veeva closed the year with 517 total customers (+117 y/y), including 145 clinical customers (+70% y/y) and 100+ quality customers (+80% y/y), a solid improvement in all key functions of pharma organizations. Veeva continues to display solid execution across all areas of the business, evidenced by 19% Commercial Cloud growth and 120% Vault growth in the fiscal year (including the Zinc Ahead acquisition), and its best in class 127% subscription services revenue retention rate. We believe Veeva is tracking ahead of its $1bn revenue run rate target for 2020 within Life Sciences and see additional opportunities for revenue growth through the expansion of certain Vault modules to areas outside of the industry. We maintain our Buy rating and we are raising our price target from $48 to $50 on shares of VEEV." (3/1/2017)
• 5. Needham & Company LLC analysts commented, " VEEV reported sustained business momentum in 4Q with revenue, EPS, and billings easily beating estimates as Vault expands sales impact to new modules and across verticals. New customer metrics accelerated in FY17 over FY16 led by Vault (115 adds vs. 84 in FY16) but CRM also had much higher new customer adds (47 vs. 16 in FY16). VEEV's Vault momentum that extended in 4Q included its two largest deals ever, two large Vault Quality wins with two top 30 global chemical companies, and its first Vault RIM deals with top 20 Pharma customers. We believe these new Vault successes yield incremental confidence that VEEV can sustain a 20% + growth profile for the next two or three years at a minimum and does not include any assumptions for EDC, which can add upside to our growth thesis if successful with initial 2Q18 trials." (3/1/2017)

Some companies that are related to Veeva Systems include athenahealth (ATHN), Cotiviti Holdings (COTV), HealthEquity (HQY), Allscripts Healthcare Solutions (MDRX), Omnicell (OMCL), Evolent Health (EVH), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), NantHealth (NH), Tabula Rasa Healthcare (TRHC), Craneware plc (CRW), Simulations Plus (SLP), Fluidigm Corporation (FLDM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Press Ganey Holdings (PGND).

Veeva Systems' management team includes the folowing people:

• Gordon Ritter, Independent Chairman of the Board
• Matthew J. Wallach, President
• Peter P. Gassner, Chief Executive Officer, Director
• Timothy S. Cabral, Chief Financial Officer
• Alan V. Mateo, Executive Vice President of Sales
• Jonathan W. Faddis, Senior Vice President, General Counsel, Corporate Secretary
• Frederic Lequient, Senior Vice President - Global Customer Services
• E. Nitsa Zuppas, Chief Marketing Officer
• Mark T. Carges, Director
• Timothy C. Barabe, Independent Director

Veeva Systems' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.53%), Artisan Partners Limited Partnership (4.54%), BlackRock Inc. (4.16%), Federated Investors Inc. PA (2.99%), FMR LLC (2.47%) and William Blair Investment Management LLC (2.16%). Company insiders that own Veeva Systems stock include Alan Mateo, Eleni Nitsa Zuppas, Frank Defesche, Frederic Lequient, Gordon Ritter, Jonathan Faddis, Mark Armenante, Matthew J Wallach, Paul J Sekhri, Ronald E F Codd, Timothy C Barabe, Timothy S Cabral and Young A Sohn. View Institutional Ownership Trends for Veeva Systems.

Veeva Systems' stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Renaissance Technologies LLC, Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Federated Investors Inc. PA, Lord Abbett & CO. LLC, Riverbridge Partners LLC and JPMorgan Chase & Co.. Company insiders that have sold Veeva Systems stock in the last year include Alan Mateo, Eleni Nitsa Zuppas, Frederic Lequient, Gordon Ritter, Jonathan Faddis, Matthew J Wallach, Paul J Sekhri, Ronald E F Codd, Timothy C Barabe and Timothy S Cabral. View Insider Buying and Selling for Veeva Systems.

Veeva Systems' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, State Street Corp, Koch Industries Inc., Sumitomo Mitsui Trust Holdings Inc., Vanguard Group Inc., American Century Companies Inc. and Swiss National Bank. View Insider Buying and Selling for Veeva Systems.

Shares of Veeva Systems can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Veeva Systems stock can currently be purchased for approximately $55.68.